• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Theratechnologies Inc. (Amendment)

    2/10/22 5:01:08 PM ET
    $THTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $THTX alert in real time by email
    SC 13G/A 1 d446427dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    THERATECHNOLOGIES, INC.

    (Name of Issuer)

    Common Stock

    (Title of Class of Securities)

    88338H100

    (CUSIP Number)

    December 31, 2021

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP NO. 88338H100

     

      1    

      NAMES OF REPORTING PERSONS

      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

      Soleus Capital Master Fund, L.P.

      2    

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

      (a)  ☐        (b)  ☐

     

      3    

      SEC USE ONLY

     

      4    

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Cayman Islands

    NUMBER OF

    SHARES

      BENEFICIALLY  

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

        5     

      SOLE VOTING POWER

     

      0

      6     

      SHARED VOTING POWER

     

      9,242,082 (1)

      7     

      SOLE DISPOSITIVE POWER

     

      0

      8     

      SHARED DISPOSITIVE POWER

     

      9,242,082 (1)

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      9,242,082 (1)

    10    

      CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    11    

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      9.6% (2)

    12    

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      FI

    FOOTNOTES

     

    (1)

    The shares of common stock reported in this row are held by Soleus Capital Master Fund, L.P. (“Master Fund”), and include a presently exercisable warrant to purchase up to 1,550,000 shares of common stock at an exercise price of $3.14 per share (the “Warrant”). Soleus Capital, LLC is the sole general partner of Master Fund and thus holds voting and dispositive power over the shares held by Master Fund. Soleus Capital Group, LLC is the sole managing member of Soleus Capital, LLC. Mr. Guy Levy is the sole managing member of Soleus Capital Group, LLC. Each of Soleus Capital Group, LLC, Soleus Capital, LLC and Mr. Guy Levy disclaims beneficial ownership of these securities held by Master Fund and this report shall not be deemed an admission that they are the beneficial owners of such securities for purposes of Section 13(d) of the Exchange Act, or for any other purpose, except to the extent of their respective pecuniary interests therein.

    (2)

    This percentage is calculated based upon 95,121,639 shares of common stock outstanding of the Issuer as of the close of business on December 15, 2021, as per the Prospectus Supplement dated December 16, 2021 that was filed by the Issuer with the U.S. Securities and Exchange Commission on December 17, 2021 (the “Prospectus Supplement”).


    CUSIP NO. 88338H100

     

      1    

      NAMES OF REPORTING PERSONS

      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

      Soleus Capital, LLC

      2    

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

      (a)  ☐        (b)  ☐

     

      3    

      SEC USE ONLY

     

      4    

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

      BENEFICIALLY  

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

        5     

      SOLE VOTING POWER

     

      0

      6     

      SHARED VOTING POWER

     

      9,242,082 (1)

      7     

      SOLE DISPOSITIVE POWER

     

      0

      8     

      SHARED DISPOSITIVE POWER

     

      9,242,082 (1)

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      9,242,082 (1)

    10    

      CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    11    

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      9.6% (2)

    12    

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      OO

    FOOTNOTES

     

    (1)

    The shares of common stock reported in this row are held by Master Fund, and include the Warrant. Soleus Capital, LLC is the sole general partner of Master Fund and thus holds voting and dispositive power over the shares held by Master Fund. Soleus Capital Group, LLC is the sole managing member of Soleus Capital, LLC. Mr. Guy Levy is the sole managing member of Soleus Capital Group, LLC. Each of Soleus Capital Group, LLC, Soleus Capital, LLC and Mr. Guy Levy disclaims beneficial ownership of these securities held by Master Fund and this report shall not be deemed an admission that they are the beneficial owners of such securities for purposes of Section 13(d) of the Exchange Act, or for any other purpose, except to the extent of their respective pecuniary interests therein.

    (2)

    This percentage is calculated based upon 95,121,639 shares of common stock outstanding of the Issuer as of the close of business on December 15, 2021, as per the Prospectus Supplement.


    CUSIP NO. 88338H100

     

      1    

      NAMES OF REPORTING PERSONS

      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

      Soleus Capital Group, LLC

      2    

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

      (a)  ☐        (b)  ☐

     

      3    

      SEC USE ONLY

     

      4    

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

      BENEFICIALLY  

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

        5     

      SOLE VOTING POWER

     

      0

      6     

      SHARED VOTING POWER

     

      9,242,082 (1)

      7     

      SOLE DISPOSITIVE POWER

     

      0

      8     

      SHARED DISPOSITIVE POWER

     

      9,242,082 (1)

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      9,242,082 (1)

    10    

      CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    11    

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      9.6% (2)

    12    

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      OO

    FOOTNOTES

     

    (1)

    The shares of common stock reported in this row are held by Master Fund, and include the Warrant. Soleus Capital, LLC is the sole general partner of Master Fund and thus holds voting and dispositive power over the shares held by Master Fund. Soleus Capital Group, LLC is the sole managing member of Soleus Capital, LLC. Mr. Guy Levy is the sole managing member of Soleus Capital Group, LLC. Each of Soleus Capital Group, LLC, Soleus Capital, LLC and Mr. Guy Levy disclaims beneficial ownership of these securities held by Master Fund and this report shall not be deemed an admission that they are the beneficial owners of such securities for purposes of Section 13(d) of the Exchange Act, or for any other purpose, except to the extent of their respective pecuniary interests therein.

    (2)

    This percentage is calculated based upon 95,121,639 shares of common stock outstanding of the Issuer as of the close of business on December 15, 2021, as per the Prospectus Supplement.


    CUSIP NO. 88338H100

     

      1    

      NAMES OF REPORTING PERSONS

      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

      Guy Levy

      2    

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

      (a)  ☐        (b)  ☐

     

      3    

      SEC USE ONLY

     

      4    

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      United States

    NUMBER OF

    SHARES

      BENEFICIALLY  

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

        5     

      SOLE VOTING POWER

     

      0

      6     

      SHARED VOTING POWER

     

      9,242,082 (1)

      7     

      SOLE DISPOSITIVE POWER

     

      0

      8     

      SHARED DISPOSITIVE POWER

     

      9,242,082 (1)

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      9,242,082 (1)

    10    

      CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    11    

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      9.6% (2)

    12    

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      IN

    FOOTNOTES

     

    (1)

    The shares of common stock reported in this row are held by Master Fund, and include the Warrant. Soleus Capital, LLC is the sole general partner of Master Fund and thus holds voting and dispositive power over the shares held by Master Fund. Soleus Capital Group, LLC is the sole managing member of Soleus Capital, LLC. Mr. Guy Levy is the sole managing member of Soleus Capital Group, LLC. Each of Soleus Capital Group, LLC, Soleus Capital, LLC and Mr. Guy Levy disclaims beneficial ownership of these securities held by Master Fund and this report shall not be deemed an admission that they are the beneficial owners of such securities for purposes of Section 13(d) of the Exchange Act, or for any other purpose, except to the extent of their respective pecuniary interests therein.

    (2)

    This percentage is calculated based upon 95,121,639 shares of common stock outstanding of the Issuer as of the close of business on December 15, 2021, as per the Prospectus Supplement.


    Item 1.

     

      (a)

    Name of Issuer

    Theratechnologies, Inc.

     

      (b)

    Address of Issuer’s Principal Executive Offices

    2015 Pearl Street, Suite 1100

    Montreal, Quebec, Canada H3A 1T8

    Item 2.

     

      (a)

    Name of Person(s) Filing

    Soleus Capital Master Fund, L.P.

    Soleus Capital, LLC

    Soleus Capital Group, LLC

    Guy Levy

     

      (b)

    Address of Principal Business Office or, if none, Residence

    Soleus Capital Master Fund, L.P.

    104 Field Point Road, 2nd Floor

    Greenwich, CT 06830

    Soleus Capital, LLC

    104 Field Point Road, 2nd Floor

    Greenwich, CT 06830

    Soleus Capital Group, LLC

    104 Field Point Road, 2nd Floor

    Greenwich, CT 06830

    Guy Levy

    c/o Soleus Capital Management, L.P

    104 Field Point Road, 2nd Floor

    Greenwich, CT 06830

     

      (c)

    Citizenship

    Soleus Capital Master Fund, L.P. – Cayman Islands

    Soleus Capital, LLC – Delaware

    Soleus Capital Group, LLC—Delaware

    Guy Levy – United States

     

      (d)

    Title of Class of Securities

    Common Stock

     

      (e)

    CUSIP Number

    88338H100


    Item 3.

    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)    ☐    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
    (b)    ☐    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c)    ☐    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. ☐78c).
    (d)    ☐    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).
    (e)    ☐    An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
    (f)    ☐    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
    (g)    ☐    A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)    ☐    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)    ☐    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)    ☐    A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J).
    (k)    ☐    Group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:

     

    Item 4.

    Ownership.

    Reference is made to Items 5 – 11 on the preceding pages of this Schedule 13G.

    As of December 31, 2021, Master Fund holds an aggregate of 9,242,082 shares of the common stock of the Issuer, including a presently exercisable warrant to purchase up to 1,550,000 shares of the common stock of the Issuer at an exercise price of $3.14 per share.

    As the general partner of Master Fund, Soleus Capital, LLC may be deemed to have shared power to vote or direct the vote and to dispose or to direct the disposition of the shares held by Master Fund. As the sole managing member of Soleus Capital, LLC, Soleus Capital Group, LLC may be deemed to have shared power to vote or to direct the vote and to dispose or direct the disposition of the shares held by Master Fund. As the sole managing member of Soleus Capital Group, LLC, Mr. Guy Levy may be deemed to have shared power to vote or direct the vote and to dispose or to direct the disposition of the Shares held by Master Fund.

    Neither the filing of this Schedule 13G nor any of its contents shall be deemed to constitute an admission that Mr. Levy, Soleus Capital, LLC or Soleus Capital Group, LLC is the beneficial owner of the shares of the common stock of the Issuer referred to herein for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, or for any other purpose, and such beneficial ownership is expressly disclaimed, except to the extent of their respective pecuniary interests therein.


    Item 5.

    Ownership of Five Percent or Less of a Class

    Not applicable.

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person.

    Not applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

    Not applicable.

     

    Item 8.

    Identification and Classification of Members of the Group

    Not applicable.

     

    Item 9.

    Notice of Dissolution of Group

    Not applicable.

     

    Item 10.

    Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose, or with the effect, of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 10, 2022     Soleus Capital Master Fund, L.P.
        By:   Soleus Capital, LLC, its General Partner
        By:   Soleus Capital Group, LLC, its Managing Manager
        By:  

    /s/ Guy Levy

        Name:   Guy Levy
        Title:   Managing Member
    Date: February 10, 2022     Soleus Capital, LLC
        By:   Soleus Capital Group, LLC, its Managing Manager
        By:  

    /s/ Guy Levy

        Name:   Guy Levy
        Title:   Managing Member
    Date: February 10, 2022     Soleus Capital Group, LLC
        By:  

    /s/ Guy Levy

        Name:   Guy Levy
        Title:   Managing Member
    Date: February 10, 2022    

    /s/ Guy Levy

        Name:   Guy Levy

    Footnotes:

    Attention:    Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)

    Get the next $THTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $THTX

    DatePrice TargetRatingAnalyst
    11/17/2022$9.00Overweight
    Cantor Fitzgerald
    7/29/2021$8.00 → $3.00Buy → Hold
    Canaccord Genuity
    More analyst ratings

    $THTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Theratechnologies Presents Novel Data at ACTHIV 2025 Underscoring Importance of Managing Excess Visceral Abdominal Fat (EVAF) in People with HIV

      VAMOS analysis highlights link between EVAF and reduced muscle quality Case series reports success with combination tesamorelin/GLP-1 receptor agonist therapy MONTREAL, May 02, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a commercial-stage biopharmaceutical company, today announced two poster presentations at the 19th Annual American Conference for the Treatment of HIV (ACTHIV 2025), taking place May 1-3 in Chicago, Ill. Both presentations focus on issues surrounding excess visceral abdominal fat (EVAF), a common comorbidity in people with HIV (PWH). One poster presents a new analysis of data from the Visceral Adiposity

      5/2/25 7:30:00 AM ET
      $THTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Theratechnologies Provides Update on Sale Process

      MONTREAL, April 15, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a commercial-stage biopharmaceutical company, today announced that following careful consideration of the current circumstances, including the publicly announced proposal from Future Pak, the Board of Directors of the Company (the "Board") has decided to further evaluate the potential sale of the Company through an open and non-exclusive process. In connection with this determination, the Board has authorized the special committee, consisting of independent and disinterested directors (the "Special Committee"), to oversee the process and make a recommendation t

      4/15/25 6:00:27 PM ET
      $THTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Soleus Capital Issues Letter to The Board of Theratechnologies

      Soleus Capital Management, L.P. ("Soleus Capital"), a healthcare investment firm which owns in excess of 10% of the stock of Theratechnologies Inc. (NASDAQ:THTX) (the "Company"), today sent a letter to the Board of Directors of the Company. In its letter, Soleus Capital described its belief that an acquisition of the Company is in the best interest of the Company's shareholders and urged the Board to pursue an acquisition offer announced earlier today by Future Pak, LLC at a price of at least $3.51 per share, representing a premium of at least 163% to the closing price of the Company on April 10th. The letter also described Soleus Capital's concern that management of the Company and the B

      4/12/25 8:46:00 AM ET
      $THTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $THTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Theratechnologies Appoints Elina Tea to its Board of Directors

      MONTREAL, April 05, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the appointment of Elina Tea, Chief Financial Officer at GLS North America, to its Board of Directors and as a member of the Company's Audit Committee. Ms. Tea will be Investissement Québec's designee pursuant to its investor rights agreement with the Company. "Elina Tea's extensive experience in finance, corporate strategy, and investor relations makes her a valuable addition to our Board of Directors," said Dawn Svoronos, Chair of the Board o

      4/5/24 11:00:00 AM ET
      $THTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Theratechnologies Appoints Jordan Zwick to its Board of Directors

      MONTREAL, March 21, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the appointment of Jordan Zwick, Chief Business Officer at Mirador Therapeutics Inc., to its Board of Directors and as a member of the Company's Audit Committee. "We welcome Jordan Zwick to the Board as an important addition to our esteemed group of advisors," said Dawn Svoronos, Chair of the Board of Directors at Theratechnologies. "With his extensive experience in the U.S. biotech and pharmaceutical industry, coupled with expertise in global

      3/21/24 8:00:00 PM ET
      $THTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Theratechnologies Announces the Resignation of One of Its Directors, Mr. Alain Trudeau

      MONTREAL, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Mr. Alain Trudeau has resigned from the Board of Directors of Theratechnologies and as a member of its Audit Committee, effective immediately. "I want to thank Alain for his contributions to Theratechnologies as a director since joining the Company in October 2020 and for completing the annual review for the 2023 fiscal year", said Dawn Svoronos, Chair of the Board at Theratechnologies. "Alain was the current Chair of the Audit Committee

      2/29/24 4:34:00 PM ET
      $THTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $THTX
    SEC Filings

    See more
    • SEC Form 6-K filed by Theratechnologies Inc.

      6-K - Theratechnologies Inc. (0001512717) (Filer)

      5/2/25 4:30:17 PM ET
      $THTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Theratechnologies Inc.

      6-K - Theratechnologies Inc. (0001512717) (Filer)

      4/16/25 10:51:02 AM ET
      $THTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Theratechnologies Inc.

      6-K - Theratechnologies Inc. (0001512717) (Filer)

      4/15/25 11:47:51 AM ET
      $THTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $THTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Theratechnologies Inc.

      SC 13G - Theratechnologies Inc. (0001512717) (Subject)

      2/14/24 4:51:41 PM ET
      $THTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Theratechnologies Inc. (Amendment)

      SC 13G/A - Theratechnologies Inc. (0001512717) (Subject)

      2/7/24 6:55:18 PM ET
      $THTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Theratechnologies Inc.

      SC 13D - Theratechnologies Inc. (0001512717) (Subject)

      11/28/23 4:52:43 PM ET
      $THTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $THTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on Theratechnologies with a new price target

      Cantor Fitzgerald initiated coverage of Theratechnologies with a rating of Overweight and set a new price target of $9.00

      11/17/22 7:27:25 AM ET
      $THTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Theratechnologies downgraded by Canaccord Genuity with a new price target

      Canaccord Genuity downgraded Theratechnologies from Buy to Hold and set a new price target of $3.00 from $8.00 previously

      7/29/21 9:53:58 AM ET
      $THTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Canaccord Genuity reiterated coverage on Theratechnologies with a new price target

      Canaccord Genuity reiterated coverage of Theratechnologies with a rating of Buy and set a new price target of $8.00 from $7.00 previously

      4/19/21 9:31:33 AM ET
      $THTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $THTX
    Financials

    Live finance-specific insights

    See more
    • Theratechnologies Reports Financial Results for the First Quarter 2025 and Reviews Key Achievements

      FDA Approves EGRIFTA WR™ (Tesamorelin F8) to Treat Excess Visceral Abdominal Fat in Adults with HIV and LipodystrophyTotal Revenue $19 million, representing +17% growth year over yearFDA Approves Prior Approval Supplement (PAS) for EGRIFTA SV® sBLALatest from VAMOS study demonstrates excess visceral abdominal fat drives cardiovascular risk MONTREAL, April 09, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a commercial-stage biopharmaceutical company, today reported business highlights and financial results for the first quarter 2025, ended February 28, 2025. All figures are in U.S. dollars unless otherwise stated. First-

      4/9/25 7:30:00 AM ET
      $THTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Theratechnologies to Announce First Quarter 2025 Financial Results and Provide Business Update

      MONTREAL, April 03, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a commercial-stage biopharmaceutical company, today announced the Company will report financial results and provide a business update for its first quarter 2025 ended February 28 on Wednesday, April 9, 2025, at 8:30 a.m. ET. The call will be hosted by Paul Lévesque, President and Chief Executive Officer, who will be joined by other members of the management team, including Philippe Dubuc, Senior Vice President and Chief Financial Officer, Christian Marsolais, Ph.D., Senior Vice President and Chief Medical Officer and John Leasure, Global Commercial Officer. Th

      4/3/25 4:30:00 PM ET
      $THTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2024

      Achieved record positive Adjusted EBITDA* of $20 million for FY2024 (net loss of $8.3 million), exceeding latest guidance of $17-19 million Achieved record quarterly revenue of $25 million and annual revenue of $85.9 million New credit facilities' favorable interest rates and amortization schedules free up approximately $19 million in cash in 2025 In-licensed two new Ionis assets in Canada to drive long-term growth MONTREAL, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a specialty biopharmaceutical company focused on the commercialization of innovative therapies that have the potential to redefine standards of

      2/26/25 7:30:00 AM ET
      $THTX
      Biotechnology: Pharmaceutical Preparations
      Health Care